Cellectis SA Total Liabilities
Cellectis SA total liabilities. Based on the latest financial reports, Cellectis SA (CLLS) has total liabilities worth $226.30 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Cellectis SA's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cellectis SA (2007–2025)
Total liabilities of Cellectis SA from 2007 to 2025. This chart illustrates how Cellectis SA's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Cellectis SA to see how much of total assets are deployed in long-term investments.
Cellectis SA Competitors by Total Liabilities
The table below lists competitors of Cellectis SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
La Kaffa International Co Ltd
TWO:2732
|
Taiwan | NT$3.60 Billion |
|
Golden Bridge Electech Inc
TW:6133
|
Taiwan | NT$822.99 Million |
|
Clearwise AG
DU:ABO
|
Germany | €251.31 Million |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
USA | $4.61 Million |
|
AMTD IDEA Group
NYSE:AMTD
|
USA | $385.38 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
USA | $28.02 Million |
|
Dimerix Ltd
AU:DXB
|
Australia | AU$77.80 Million |
|
OncoQuest Pharmaceuticals Inc
KQ:078590
|
Korea | ₩19.38 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Cellectis SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cellectis SA balance sheet assets.
Liquidity & Leverage Metrics
Cellectis SA Total Liabilities Ratios Explained
Cellectis SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis SA (2007–2025)
The table below shows the annual total liabilities of Cellectis SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $248.82 Million | -1.46% |
| 2024-12-31 | $252.51 Million | +1.18% |
| 2023-12-31 | $249.57 Million | +84.49% |
| 2022-12-31 | $135.28 Million | -7.09% |
| 2021-12-31 | $145.60 Million | -9.35% |
| 2020-12-31 | $160.62 Million | +43.42% |
| 2019-12-31 | $112.00 Million | +121.48% |
| 2018-12-31 | $50.57 Million | +7.64% |
| 2017-12-31 | $46.98 Million | -17.05% |
| 2016-12-31 | $56.63 Million | -33.11% |
| 2015-12-31 | $84.67 Million | -10.83% |
| 2014-12-31 | $94.95 Million | +153.46% |
| 2013-12-31 | $37.46 Million | +12.10% |
| 2012-12-31 | $33.42 Million | -64.77% |
| 2011-12-31 | $94.86 Million | +396.58% |
| 2010-12-31 | $19.10 Million | +5.44% |
| 2009-12-31 | $18.12 Million | +23.92% |
| 2008-12-31 | $14.62 Million | +41.54% |
| 2007-12-31 | $10.33 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more